Clinical Trial Update: Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment [Phase 2]

View source ↗

Summary

Clinical trial update announcing a phase 2 study of lenvatinib in combination with pembrolizumab for anal or rectal cancer that progressed after initial therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Rectal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: University of Chicago | Conditions: Carcinoma, Squamous Cell, Anorectal Cancer | Phase 2 | Status: RECRUITING